Additionally, given the promise of the dual GIP/GLP-1 agonist tirzepatide for the treatment of obesity in people with T2D, further trials exploring cardiovascular outcomes with this drug would be welcome to support its use in routine clinical practice. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.